We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
Read MoreHide Full Article
Key Takeaways
Hims & Hers runs a proprietary digital platform linking providers, personalized plans and ongoing care.
HIMS launched Labs for biomarker tracking, feeding provider action plans and deeper personalization.
Hims & Hers acquired YourBio Health and invested in AI to integrate diagnostics with digital care delivery.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates as a digital healthcare platform built on proprietary technology that integrates care delivery, data and fulfillment into a single, consumer-facing ecosystem. Its platform connects users to licensed providers, personalized treatment plans and ongoing care management through owned websites and mobile applications. HIMS emphasizes that its technology improves with scale, as each interaction strengthens its data backbone, enabling more intelligent personalization, clinical decision-making and continuity of care across specialties.
Recent developments highlight how this proprietary platform is expanding beyond episodic treatment toward a more proactive, data-driven model. The launch of Labs introduced longitudinal biomarker tracking that feeds directly into provider-developed action plans, deepening personalization across conditions. Hims & Hers has also continued to invest in artificial intelligence (AI) and platform infrastructure to enhance diagnostics, treatment matching and care orchestration, reinforcing the role of software and data as core differentiators rather than support functions.
Strategic initiatives further underscore this platform-led approach. The acquisition of YourBio Health brings patented, pain-free blood sampling technology in-house, allowing tighter integration between diagnostics and digital care delivery. Combined with ongoing investments in technology leadership and AI capabilities, these moves position Hims & Hers as a healthcare platform where proprietary systems, data feedback loops and vertically integrated innovation work together to scale personalized care.
GDRX and DOCS Scaling Healthcare Through Proprietary Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) operates as a digital healthcare platform built on proprietary technology that connects consumers, pharmacies and manufacturers through integrated pricing and access solutions. GoodRx leverages its platform to power tools such as RxSmartSaver and Community Link, while expanding into condition-specific digital care. Recent launches in weight loss, erectile dysfunction and hair loss show how GoodRx uses its technology to combine pricing intelligence, virtual consultations and prescription fulfillment into a single, scalable healthcare experience.
Doximity, Inc. (DOCS - Free Report) operates as a digital healthcare platform built on proprietary technology designed specifically for medical professionals. Doximity connects physicians through a verified network that integrates clinical news, workflow tools, telehealth and AI-powered solutions into daily practice. Recent developments, including the integration of Pathway’s AI clinical reference and the rapid adoption of DocsGPT and AI workflow tools, highlight how Doximity is using proprietary data, trusted content and software to deepen engagement and embed itself further into the clinical decision-making process.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 44.8% over the past year, underperforming the industry’s decline of 35.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.9X is lower than the industry’s average of 3.7X and its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 85.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates as a digital healthcare platform built on proprietary technology that integrates care delivery, data and fulfillment into a single, consumer-facing ecosystem. Its platform connects users to licensed providers, personalized treatment plans and ongoing care management through owned websites and mobile applications. HIMS emphasizes that its technology improves with scale, as each interaction strengthens its data backbone, enabling more intelligent personalization, clinical decision-making and continuity of care across specialties.
Recent developments highlight how this proprietary platform is expanding beyond episodic treatment toward a more proactive, data-driven model. The launch of Labs introduced longitudinal biomarker tracking that feeds directly into provider-developed action plans, deepening personalization across conditions. Hims & Hers has also continued to invest in artificial intelligence (AI) and platform infrastructure to enhance diagnostics, treatment matching and care orchestration, reinforcing the role of software and data as core differentiators rather than support functions.
Strategic initiatives further underscore this platform-led approach. The acquisition of YourBio Health brings patented, pain-free blood sampling technology in-house, allowing tighter integration between diagnostics and digital care delivery. Combined with ongoing investments in technology leadership and AI capabilities, these moves position Hims & Hers as a healthcare platform where proprietary systems, data feedback loops and vertically integrated innovation work together to scale personalized care.
GDRX and DOCS Scaling Healthcare Through Proprietary Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) operates as a digital healthcare platform built on proprietary technology that connects consumers, pharmacies and manufacturers through integrated pricing and access solutions. GoodRx leverages its platform to power tools such as RxSmartSaver and Community Link, while expanding into condition-specific digital care. Recent launches in weight loss, erectile dysfunction and hair loss show how GoodRx uses its technology to combine pricing intelligence, virtual consultations and prescription fulfillment into a single, scalable healthcare experience.
Doximity, Inc. (DOCS - Free Report) operates as a digital healthcare platform built on proprietary technology designed specifically for medical professionals. Doximity connects physicians through a verified network that integrates clinical news, workflow tools, telehealth and AI-powered solutions into daily practice. Recent developments, including the integration of Pathway’s AI clinical reference and the rapid adoption of DocsGPT and AI workflow tools, highlight how Doximity is using proprietary data, trusted content and software to deepen engagement and embed itself further into the clinical decision-making process.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 44.8% over the past year, underperforming the industry’s decline of 35.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.9X is lower than the industry’s average of 3.7X and its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests an 85.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.